Clostridium difficile toxins A and B are major virulence factors responsible for induction of pseudomembranous colitis and antibiotic-associated diarrhea in men. The toxins possess a multidomain structure and only the N-terminal glucosyltransferase domain, which inactivates Rho GTPases by glucosylation, is translocated into the cytosol of target cells. Processing of the toxin occurs by auto-catalytic cleavage and is activated by inositol hexakisphosphate (InsP 6 ). Here we studied the inherent protease activity in fragments of toxin B and determined the site of toxin B that interacts with InsP 6 . We report that a fragment of toxin B, comprised of residues 1-955, is cleaved in the presence of InsP 6 . In contrast, mutants of the catalytic triad of the putative cysteine protease domain did not cleave this fragment. [ 3 H]InsP 6 bound to holotoxin B and to the fragment 1-955, but not to a fragment comprising residues 900-2366 or the glucosyltransferase domain (residues 1-544). Binding to the putative cysteine protease domain (residues 544-955) was also observed. InsP 6 -binding was specific and saturable. Isothermal titration calorimetry revealed a K d value of 2.4 µM for binding of InsP 6 to toxin fragment 544-955 with a stoichiometry factor of 0.86. Lysine600 of toxin B was identified as essential amino acid for InsP 6 -binding and for InsP 6 -dependent activation of the protease activity.
Clostridium difficile toxins A and B are the causative agents of pseudomembranous colitis. In even more cases, the toxins are responsible for antibiotic-associated diarrhea, which is a frequent complication occurring during or after therapy with antibiotics (1) (2) (3) . Both toxins belong to the family of clostridial glucosylating toxins, which inactivate eukaryotic GTPases of the Rho family by attachment of glucose (4;5). The C. difficile toxins A and B are multi-functional proteins with molecular masses of 269 and 308 kDa (5) (6) (7) . After binding of the C-terminus to the cell surface receptors of target cells (8;9) , the toxins are endocytosed and traffic to early endosomes (10;11) . The acidic compartment causes conformational changes of the toxin molecule and allows insertion of an internally located hydrophobic region (residues 956-1128) into vesicle membranes (12) (13) (14) , which is accompanied by pore-formation and subsequent translocation into the cytosol (15;16) . Only the N-terminal glucosyltransferase domain (17) , consisting of ~540 amino acid residues, is released into the cytosol of target cells (18;19) , where it then modifies Rho GTPases (4) . Cleavage of the toxins occurs by an auto-catalytic process, which is largely enhanced by inositol hexakisphosphate (InsP 6 ) and dithiothreitol (12;14) . It has been proposed previously that an aspartate protease activity, which is characterized by the DSG motif located at position 1665, is involved in auto-catalytic cleavage (12) . However, we and others (13;14) have proposed that a cysteine protease domain located near the N-terminal glucosyltransferase domain is responsible for the cleavage and processing of the toxins. To clarify the localization of the protease activity in more detail, we constructed and characterized a series of toxin deletion mutants. Here we report that the toxin fragment 1-955 is sufficient for processing and release of the glucosyltransferase domain. Moreover, we show that InsP 6 binds to a region, consisting of amino acids 544-955 and identified lysine at position 600 as essential for interaction with InsP 6 .
EXPERIMENTAL PROCEDURES
Bacterial Strains and Reagents-E. coli BL21(DE3) (Invitrogen, Karlsruhe, Germany) and TG1 bacteria (Stratagene, La Jolla, CA) were cultivated in LB-broth (Luria/Miller; Carl Roth GmbH, Karlsruhe, Germany) at 37°C if not otherwise mentioned. Oligonucleotides were purchased from Apara Bioscience GmbH (Freiburg, Germany). Toxin B specific primers for site-directed mutagenesis to generate the following amino acid substitutions: K600E, K689E, R751E/R752E and H653A/C698A, were designed according to the cDNA sequence of toxin B from Clostridium difficile strain VPI 10463 (Gen Bank acc. nr. X53138). Inositol hexakisphosphate, myo-inositol 1,4,5 trisphosphate, myo-inositol hexasulfate, proteinase K and thrombin were purchased from SigmaAldrich (Taufkirchen, Germany), benzamidineSepharose 6B and glutathione-Sepharose 4B from GE Healthcare/Amersham (Munich, Germany), isopropyl β-D-thiogalactoside from PeqLab Biotechnology GmbH (Erlangen, Germany) and guanosine-5´-O-(3-thiotriphosphate) from Roche Diagnostics GmbH (Mannheim, Germany).
Cloning of Toxin B Fragments-For toxin B fragments 1-955, 544-955 and 579-777 primers were designed to amplify fragments of C. difficile toxin B with flanking BamHI and NotI restriction sites from genomic DNA of C. difficile VPI 10463 (toxinB-1-BamHI-sense (cccggatccatgagtttagttaatagaaaacag), toxinB-544-BamHI-sense (cggatccggtgaagatgataatcttg) and toxinB-955-NotI-antisense (cgcggccgcttcgtgtgtagtatctaaatttac); toxinB-579-BamHI-sense (cggatcccactatattgttcagttacaagg) and toxinB-777-NotI-antisense-stop (cgcggccgctcattcttttgatgaaatatcatttataatactttc). PCR was performed by using Pfu Turbo polymerase (Fermentas GmbH, St. Leon-Rot, Germany) and the PCR products were cloned into pCR-BluntII-TOPO vector (Invitrogen, Karlsruhe, Germany), then subcloned into pET-28a(+) (Novagen, EMD Biosciences) as BamHI-NotI fragments. Primers for amplification of toxin B fragment 544-2366 and toxin B fragment 900-2366 were toxinB-544-BamHI-sense (cggatccggtgaagatgataatcttg) and toxinB-2366-EcoRI-antisense (gaattcctattcactaatcactaattg), and toxinB-900-BamHI-sense (cggatcctttattaataaagaaactggagaatc) and toxinB-2366-XhoI-antisense (cctcgagctattcactaatcactaattg), respectively. The generated PCR products were cloned into pGEX4T-1 vector (toxin B 544-2366) and pGEX2T vector (toxin B 900-2366) (Amersham Pharmacia Biotech, Uppsala, Sweden). Toxin B fragment 1-544 was cloned as already described (14;18;20) . In Vitro Cleavage Assay and Western BlottingCleavage assays were performed in 100 mM TrisHCl buffer, pH 7.5, at a final volume of 20 µl with 1 µg toxin B. Reactions were initiated by addition of InsP 6 or InsS 6 at indicated final concentrations and were incubated for 30 min at 23 °C. The reaction was stopped by heating the samples at 95 °C in Laemmli buffer and probes were separated by SDS-PAGE (3-12% gradient gel). Proteins were transferred to PVDF membrane with a semidry blotter (BioRad, Munich, Germany). Monoclonal anti-toxin B 1-546 antibody at a dilution of 1:100.000 followed by the anti-mouse IgG HRP secondary antibody (1:5000; Biotrend, Cologne, Germany) was used for detection of the catalytic domain of toxin B. Corresponding bands were detected using enhanced chemiluminescence (ECL). Isothermal Titration Calorimetry-The interaction between InsP 6 and toxin B fragment 544-955-His was characterized by isothermal titration calorimetry (ITC200, MicroCal, Milton Keynes, UK) using LEW-buffer pH 8.0 (50 mM NaH 2 PO 4 , 300 mM NaCl) at 20 °C. The cell was filled with 36 µM protein and from the syringe 2 µl aliquots of 300 µM InsP 6 were injected. As a control, the same InsP 6 solution was injected into the cell filled with buffer only. For data evaluation the manufacturer's software was used. 
Generation of Point Mutations within the

In Vitro Transcription/Translation of Toxin
Proteinase K Digestion Assay-
RESULTS
We expressed the C. difficile toxin B fragment 1-955 by in vitro transcription/translation. When InsP 6 was added to this toxin fragment, cleavage was induced (Fig. 1A) . As expected, mutations (D587N, H653A, C698A) of the putative catalytic cysteine protease triad inhibited cleavage of mutants (Fig. 1B) . The concentration of InsP 6 to stimulate auto-cleavage was in the same range as observed previously for auto-catalytic cleavage of the holotoxin (12) starting at ~1 µM. These data indicated that InsP 6 acts in a region encompassed by amino acids 1-955. Because of the evident potency of InsP 6 to cleave toxin B, we were prompted to study direct binding of InsP 6 to the protein toxin. For this purpose several toxin fragments, as well as the holotoxin B (see Fig. 2A 2C) as well as for the holotoxin B albeit to a lower extent than with fragment 1-955. We were not able to detect binding to holotoxin A. This is probably due to the fact that the affinity for InsP 6 is lower. Accordingly, it has been reported that much higher concentration of InsP 6 (1-10 mM) is necessary for induction of auto-cleavage of toxin A than for that of toxin B (12;14) . No binding was detected with the toxin B fragment 900-2366, which starts after the proposed cysteine protease domain (Fig. 2C ). This finding is in line with the hypothesis that InsP 6 interacts with the N-terminal residues 1-955 of the toxin (14) . Previously reported data did not exclude the possibility that InsP 6 also interacts with the glucosyltransferase domain of the toxin. (Fig. 3) . In order to obtain precise information about the affinity as well as the stoichiometry of the complex we employed isothermal titration calorimetry (Fig. 4) 6 . This is in line with the previously reported specificity of inositol phosphates to induce toxin cleavage (12) . We also observed that InsS 6 not only competed with [ 3 H]InsP 6 binding but also induced auto-catalytic processing of holotoxin B at high concentrations (Fig. 5B) .
The highly charged InsP 6 is likely to interact with positively charged amino acids of the toxin. We compared the sequences of the putative cysteine protease domains from the various clostridial glucosylating toxins to identify conserved lysine and arginine residues. Accordingly, two lysines (lysine 600 and lysine 689) in the protease domain of toxin B, which were identically positioned in other clostridial toxins and even conserved in the related RTX toxin, were changed to glutamate in the toxin fragment 1-955. We also made a double mutant of two arginine residues (Arg751/Arg752), which were either arginine or lysine in the other clostridial toxins or in RTX (Suppl. Fig. 2 ). The mutant toxin fragments (residues 1-955) were expressed as 14 C-labeled proteins by in vitro transcription/translation. The cleavage of the labeled proteins was studied in the absence and presence of InsP 6 (10 mM). As shown in Fig. 6A , the mutant K600E of fragment 1-955 was not longer cleaved, whereas K689E exhibited no change in cleavage as compared to the wild-type fragment. Also the double mutants R751E/R752E were not cleaved after addition of InsP 6 (Fig. 6B) . In contrast, the K600E mutant, which was not auto-catalytically cleaved (Fig. 6A) , was also not able to bind [ 3 H]InsP 6 . This result was confirmed by the identical mutation in fragment 544-955-His of toxin B (Fig.  6B) . To detect possible structural consequences of InsP 6 -binding to the toxin fragment, we performed a proteinase K digestion assay with in vitro transcribed and translated 14 C-labeled toxin B fragment 544-955. Proteinase K was able to completely cleave the toxin B fragment. However, when InsP 6 was added, a ~30 kDa fragment remained (Fig. 7) . In line with the InsP 6 -binding data, the K600E mutant of fragment 544-955, which was not able to bind InsP 6 , was not protected against degradation by proteinase K.
DISCUSSION
Clostridial glucosylating toxins are processed by auto-catalytic cleavage. Recent studies suggested a aspartate activity around residue 1665 (12) . However, in analogy with the cysteine protease activity of RTX toxin from Vibrio cholerae, we and others proposed a cysteine protease activity in the region covering residues 544-955 (13;14) . To resolve this discrepancy, we undertook studies to determine the localization of the protease activity in toxin B. By using a transcription/translation method different from that applied previously (14), we were able to express uncleaved toxin B fragment 1-955. When InsP 6 was added to this fragment, cleavage of the toxin B fragment into two parts was detected. Moreover, this processing was blocked with mutants of the putative active site of the cysteine protease. The data corroborate our previous hypothesis that auto-catalytic cleavage is caused by a putative cysteine protease located in the region 544-955. Although the precise function of InsP 6 is not clear, this highly charged molecule might activate cleavage by inducing structural changes in the protease domain and perhaps also in the glucosyltransferase domain. To gain further insights into the role of InsP 6 , we performed binding studies with radioactive labeled InsP 6 . We detected binding of InsP 6 in the protease domain but not in the catalytic domain. Moreover, a toxin B fragment, consisting of the glucosyltransferase domain and the protease domain, exhibited similar binding properties as the protease activity domain alone, indicating that the N-terminal glucosyltransferase has no effect on InsP 6 binding. Binding was also observed with mutants (H653A and C698A) of the protease active site, indicating that the enzyme activity of the protease is not essential for binding. We identified lysine600 as an essential residue for binding of InsP 6 . This residue is conserved in all clostridial glucosylating toxins and also in the RTX toxin. In line with the InsP 6 -binding data, we observed that the Lys600 mutants of fragment 1-955 were not cleaved in the presence of InsP 6 . Additionally, we observed that change of Arg751/Arg752 to glutamate blocked cleavage of the toxin fragment in the presence of InsP 6 . We propose that these residues are also involved in interaction with InsP 6 (see below). Altogether, the data indicate that inhibition of InsP 6 -binding also blocks auto-catalytic cleavage of the toxin fragment. So far the molecular mechanism of the action of InsP 6 on the cysteine protease activity of toxin B is not clear. It has been shown that InsP 6 can cause major changes in the structure of proteins after binding (23). More recently, the crystal structure of cysteine protease domain of the Vibrio cholerae RTX toxin in complex with InsP 6 has been solved (24). Deduced from this study it has been suggest that InsP 6 causes an allosteric switch, which activates the cysteine protease domain of RTX.
Major changes in the structure of the cysteine protease domain also appear to occur after binding of InsP 6 to toxin B as evidenced from the effect of InsP 6 on the protein stability in the presence of proteinase K. Addition of InsP 6 prevented complete degradation of the protease domain (residues 544-955) of toxin B by proteinase K. The effect was specific for InsP 6 and was not observed with the mutant fragment of toxin B, which is not able to bind InsP 6 , excluding the possible action of the highly charged compound on proteinase K activity or on chelation of cations. Mass spectrometric data suggest that the ~30 kDa fragment covers at least amino acid residues 544-798 (data not shown).
Prochazkova and Satchell reported recently on the binding of InsP 6 to the cysteine protease domain of RTX toxin (25). Similar as reported here, the authors found that the equivalent residue in RTX to that of Lys600 of toxin B is also important for interaction with InsP 6 . However, our findings with toxin B differ in several important aspects from that reported for RTX toxin. Prochazkova and Satchell suggested that InsP 6 interacts in a catalytic manner with RTX protease and is released after cleavage (25). Therefore, the RTX protease domain by itself is not able to bind InsP 6 after cleavage and also inactive RTX protease cannot bind InsP 6 . In contrast, we observed binding with the protease domain in the absence of the glucosyltransferase domain. Furthermore, mutants of the active site of the cysteine protease of toxin B were still able to bind InsP 6 . The recently obtained crystal structure of the cysteine protease domain of RTX toxin (24) confirms the role of conserved lysine (e.g., Lys600 in toxin B and Lys3482 in RTX) and arginine (e.g., Arg751 in toxin B and Arg3610 in RTX) residues in binding of InsP 6 . The structural data may also explain why no InsP 6 -binding was obtained with a fragment of toxin B, consisting of amino acids 579-777, which includes the proposed catalytic residues of the protease and the region that is highly similar to the auto-catalytic protease domain of the RTX toxin. However, this fragment lacks additional N-terminal and C-terminal residues, which appear to be involved in InsP 6 binding in the related RTX toxin (e.g. residues Arg575 and Lys788 of toxin B might be equivalent to the essential residues Arg3457 and Lys3628 in RTX) (Suppl. 2). Although surprising similarities exist between toxin B and the distantly related protease domain of RTX, even among the family of clostridial glucosylating toxins major differences in the interaction of InsP 6 with the protease domain are evident. For example, InsP 6 exhibits ~1,000-fold lower potency in activation of the auto-catalytic processing of toxin A, as compared to toxin B (12;14) . Therefore, it is likely that the various clostridial toxins differ in their mode of activation of their auto-catalytic protease domain. 6 , GTPγS or InsP 3 were added at increasing concentrations (0-1000 µM) and incubation was continued for further 30 min. Thereafter, the mixture was rapidly filtered through nitrocellulose membranes and washed. Bound radioactivity was monitored by liquid scintillation counting. Radioactivity (cpm) bound to toxin B fragment in the absence of unlabeled competitors was set to 100% (control). Data (cpm) for [ 3 H]InsP 6 -binding in the presence of InsP 6 , InsS 6 , GTPγS and InsP 3 are given as percent of control ± SEM of 3 independent experiments. Toxin B fragment used in these experiments was purified without the last anion chromatography. (B) Western-blot analyses of InsS 6 -or InsP 6 -induced auto-proteolysis of native holotoxin B. Full length toxin B (1 µg) was incubated for 30 min with 10 mM InsP 6 or InsS 6 at 23 °C in 100 mM TrisHCl (7.4). Thereafter, proteins were analyzed by SDS-PAGE and Western-blotting, using a monoclonal antibody specific for the glucosyltransferase domain of toxin B, which detects full length toxin (f.l.) and C-terminal part of the toxin (C.term.). 
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